Advertisement

Fischer K, Al-Sawaf O, Fink A-M, et al. Venetoclax and obinutuzumab in chronic lymphocytic leukemia. Blood. 2017;129(19):2702-2705.

On page 2702 in the 11 May 2017 issue, there is an error in the dosage of obinutuzumab in line 7 of the second paragraph. The text “100 mg on day 1900 mg on day 2” should read “100 mg on day 1 and 900 mg on day 2.” The error has been corrected in the online version, which now differs from the print version.